Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

04-01-2018 | Breast cancer | Article

Using Resistin, glucose, age and BMI to predict the presence of breast cancer

Journal: BMC Cancer

Authors: Miguel Patrício, José Pereira, Joana Crisóstomo, Paulo Matafome, Manuel Gomes, Raquel Seiça, Francisco Caramelo

Publisher: BioMed Central

Login to get access

Abstract

Background

The goal of this exploratory study was to develop and assess a prediction model which can potentially be used as a biomarker of breast cancer, based on anthropometric data and parameters which can be gathered in routine blood analysis.

Methods

For each of the 166 participants several clinical features were observed or measured, including age, BMI, Glucose, Insulin, HOMA, Leptin, Adiponectin, Resistin and MCP-1. Machine learning algorithms (logistic regression, random forests, support vector machines) were implemented taking in as predictors different numbers of variables. The resulting models were assessed with a Monte Carlo Cross-Validation approach to determine 95% confidence intervals for the sensitivity, specificity and AUC of the models.

Results

Support vector machines models using Glucose, Resistin, Age and BMI as predictors allowed predicting the presence of breast cancer in women with sensitivity ranging between 82 and 88% and specificity ranging between 85 and 90%. The 95% confidence interval for the AUC was [0.87, 0.91].

Conclusions

These findings provide promising evidence that models combining age, BMI and metabolic parameters may be a powerful tool for a cheap and effective biomarker of breast cancer.
Literature
1.
Crisóstomo J, et al. Hyperresistinemia and metabolic dysregulation: the close crosstalk in obese breast cancer. Endocrine. 2016;53(2):433-42.
2.
Cole KD, He HJ, Wang L. Breast cancer biomarker measurements and standards. Proteomics Clin Appl. 2013;7(1–2):17–29.CrossRefPubMed
3.
Hwa HL, et al. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract. 2008;14(2):275–80.CrossRefPubMed
4.
Santillan-Benitez JG, et al. The tetrad BMI, Leptin, Leptin/Adiponectin (L/a) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013;27(1):12–20.CrossRefPubMed
5.
Dalamaga M, et al. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013;46(7–8):584–90.CrossRefPubMed
6.
Assiri AM, Kamel HF. Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer. Obes Res Clin Pract. 2015;10(4):442-53.
7.
Patrício, M. and F. Caramelo, Comment on "evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and vistafin in postmenopausal breast cancer". Obesity Research & Clinical Practice, 2016.
8.
Provatopoulou X, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1):898.CrossRefPubMedPubMedCentral
9.
Witten, I.H., E. Frank, and M.A. Hall, Data Mining: Practical Machine Learning Tools and Techniques. 3rd ed. Morgan Kaufmann; 2011.
10.
Kloten V, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.CrossRefPubMedPubMedCentral
11.
Opstal-van Winden AW, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 2012;13(10):13587–604.CrossRefPubMedPubMedCentral
12.
Zhu Q, et al. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Res. 2014;16(5):456.CrossRefPubMedPubMedCentral
13.
Chlebowski RT, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–705.CrossRefPubMed
14.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.CrossRefPubMed
15.
Khakpour G, et al. DNA methylation as a promising landscape: a simple blood test for breast cancer prediction. Tumour Biol. 2015;36(7):4905–12.CrossRefPubMed
16.
Zheng BC, Yoon SW, Lam SS. Breast cancer diagnosis based on feature extraction using a hybrid of K-means and support vector machine algorithms. Expert Syst Appl. 2014;41(4):1476–82.CrossRef
17.
Maglogiannis I, Zafiropoulos E, Anagnostopoulos I. An intelligent system for automated breast cancer diagnosis and prognosis using SVM based classifiers. Appl Intell. 2009;30(1):24–36.CrossRef
18.
Aličković E, Subasi A. Breast cancer diagnosis using GA feature selection and rotation Forest. Neural Comput & Applic. 2017;28(4):753–63.
19.
Wolberg WH, Mangasarian OL. Multisurface method of pattern separation for medical diagnosis applied to breast cytology. Proc Natl Acad Sci U S A. 1990;87(23):9193–6.CrossRefPubMedPubMedCentral
20.
Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644–7.CrossRefPubMed
21.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.CrossRefPubMed
22.
Gromski PS, et al. A comparative investigation of modern feature selection and classification approaches for the analysis of mass spectrometry data. Anal Chim Acta. 2014;829:1–8.CrossRefPubMed
23.
Xu QS, Liang YZ. Monte Carlo cross validation. Chemom Intell Lab Syst. 2001;56(1):1–11.CrossRef
24.
Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–92.CrossRefPubMed
25.
van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol. 2014;14:137.CrossRefPubMedPubMedCentral
26.
Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:17.CrossRef
27.
Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.CrossRefPubMedPubMedCentral
28.
Jin J. Breast cancer screening guidelines in the United States. JAMA. 2015;314(15):1658.CrossRefPubMed
Image Credits